1. Market cap back above NYSE minimum requirements for listing. If we hold an R/S is far less likely (if it ever really was). Perhaps better put as the fear of an R/S, making the Q a more compelling investment than a company about to do a 5:1 reverse.
2. An indication that patience pays, and that the testing cycle for the product is a longer one than many had realized. Given this, the other makers we're being tested in become a much more plausible possibility. As a spec buy, the Q seems consequently far more attractive.